About Continuus Pharma
Continuus Pharma is a company based in Woburn (United States) founded in 2012. Continuus Pharma has raised $7.73 million across 7 funding rounds from investors including Industria Macchine Automatiche, Mark Bamforth and National Science Foundation. The company has 47 employees as of December 31, 2022. Continuus Pharma operates in a competitive market with competitors including Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
- Headquarter Woburn, United States
- Employees 47 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Continuus Pharmaceuticals
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.73 M (USD)
in 7 rounds
-
Latest Funding Round
$5 M (USD), Series B
Aug 26, 2019
-
Investors
Industria Macchine Automatiche
& 2 more
-
Employee Count
47
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Continuus Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Continuus Pharma
Continuus Pharma has successfully raised a total of $7.73M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $5 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Continuus Pharma
Continuus Pharma has secured backing from 3 investors, including angel and institutional investors. Prominent investors backing the company include Industria Macchine Automatiche, Mark Bamforth and National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Automated packaging machinery is manufactured for multiple industries.
|
Locked | Locked | Locked | |
|
A government-backed foundation providing seed-stage investments to support small businesses.
|
Locked | Locked | Locked | |
|
MB
Mark Bamforth |
-
|
Locked | Locked | Locked |
Investor details for Continuus Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Continuus Pharma
Investment portfolio details for Continuus Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Continuus Pharma
Detailed financials for Continuus Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Continuus Pharma Comparisons
Peer comparison for Continuus Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Continuus Pharma
Continuus Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Integrated CDMO services for biopharma R&D and manufacturing are offered.
|
|
| Locked | Locked | Locked |
APIs manufacturing and formulation services are provided in therapeutic segments.
|
|
| Locked | Locked | Locked |
APIs and enzymes are manufactured through fermentation by the CDMO.
|
|
| Locked | Locked | Locked |
APIs and finished products are developed and manufactured.
|
|
| Locked | Locked | Locked |
Generic biocatalytic solutions are provided for pharmaceutical applications.
|
|
| Locked | Locked | Locked |
APIs and peptides are developed and manufactured by Asymchem.
|
Detailed competitors of Continuus Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Continuus Pharma
Complete news archive for Continuus Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Continuus Pharma
Continuus Pharma was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Continuus Pharma is headquartered in Woburn, United States. It is registered at Woburn, Massachusetts, United States.
Continuus Pharma is a funded company, having raised a total of $7.73M across 7 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Continuus Pharma is 47.
Formed as a spinout company of the 65M collaboration between MIT and Novartis, Continuus Pharma offers one stop solutions for the development and manufacturing of continuous manufacturing solutions by removing the walls between API and FDF manufacturing. Their proprietary Integrated Continuous Manufacturing (ICM) technology for small molecule pharmaceuticals integrates the entire API and FDF manufacturing process into a continuous and seamless process and offers capabilities for on-demand manufacturing of pharmaceuticals and thus significant advantages w.r.t lead time, costs and quality. Apart from integrated solutions, they also offer targeted solutions for a wide range of unit operations such as a continuous reactor to handle solids in flow, membrane separator by-pass, heterogeneous crystallization, integrated nucleator and tubular crystallizers, continuous filtration, continuous dryer, extrusionforming and thin filmelectrospinning.
Continuus Pharma's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group.
Continuus Pharma has 3 investors. Key investors include Industria Macchine Automatiche, Mark Bamforth, and National Science Foundation.